Otsuka Group News

Keyword search

Add search criteria

Search by company

Otsuka Holdings
Otsuka Pharmaceutical
Otsuka Pharmaceutical Factory
Taiho Pharmaceutical
Otsuka Warehouse
Otsuka Chemical
Otsuka Foods
Otsuka Medical Devices
Other

Search by category^*

Pharmaceuticals Business
Nutraceuticals Business
Consumer Products Business
Others
Products
R&D
Personnel
Corporate

* Business categories are based on the business segments described in the financial announcements.

Search by release date

-

Showing 50 results

Search by release date:: Jan, 2010 ～ Dec, 2010

December 27, 2010
Otsuka Holdings

Notice Concerning Loan Transaction Stocks Assignment
December 21, 2010
Otsuka Pharmaceutical

Starting co-promotion of the anti-cancer agent “SPRYCEL® Tablet 20mg and SPRYCEL® Tablet 50mg” (dasatinib) in Japan
December 20, 2010
Taiho Pharmaceutical

TEYSUNO™ (S-1) RECEIVES CHMP POSITIVE OPINION FOR APPROVAL AS FIRST-LINE THERAPY FOR ADVANCED GASTRIC CANCER
December 17, 2010
Otsuka Pharmaceutical

The results of a subset analysis of Japanese patients from the DASISION trial comparing SPRYCEL® (dasatinib) with imatinib in the treatment of newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia.
December 16, 2010
Otsuka Holdings

Defendants Appeal From Final Judgment in U.S. Abilify® Patent Litigation
December 15, 2010
Otsuka Holdings

Consolidated Financial Results for the Second Quarter of the Fiscal Year Ending March 31, 2011 [Japan GAAP]
December 15, 2010
Otsuka Holdings

Otsuka Holdings listed on the First Section of the Tokyo Stock Exchange
December 10, 2010
Otsuka Pharmaceutical

World's First Aquaretic Agent for the Treatment of Volume Overload in Patients with Heart Failure Samsca® Tablets 15mg (tolvaptan), Vasopressin V2-Receptor Antagonist, to be Launched in Japan on December 14
December 9, 2010
Otsuka Pharmaceutical

Tokushima Itano Factory Recognized Among "Corporate Greening Linked to Conservation of Biodiversity: Best 100" Sole factory manufacturing medical-use pharmaceuticals to receive recognition
December 7, 2010
Otsuka Pharmaceutical

Follow-Up Results from Study Comparing SPRYCEL® (dasatinib) to Imatinib in First-Line Treatment of Adults with Ph+ CP-CML Demonstrate Improved Response Rates Consistent with 12 Month Data
November 19, 2010
Otsuka Pharmaceutical

Toward a Factory that is Friendly to Both the Environment and People The Tokushima Itano Factory Helps to Support the Asan Earth Festival in Itano to be Held on November 23, 2010
November 18, 2010
Otsuka Pharmaceutical

Otsuka Pharmaceutical Files Application in Japan for Additional Indication of L-Cartin® Tablets for Carnitine Deficiency, Based on Evidences in Public Domain
November 16, 2010
Otsuka Pharmaceutical

Otsuka Prevails in U.S. Abilify® Patent Litigation
November 16, 2010
Otsuka Holdings

Otsuka Prevails in U.S. Abilify® Patent Litigation
November 11, 2010
Otsuka Pharmaceutical

Clinical tests in Japan demonstrate research results relating to the efficacy of "Ion supply drink" for dehydration after bathing
November 9, 2010
Otsuka Pharmaceutical

Otsuka Pharmaceutical Files for Regulatory Approval in Japan for Mucosta® Ophthalmic Suspension for Dry Eye
November 1, 2010
Otsuka Pharmaceutical

FDA Approves SPRYCEL® (dasatinib) as Treatment for Adult Patients with Newly Diagnosed Ph+ Chronic Myeloid Leukemia in Chronic Phase
October 27, 2010
Otsuka Pharmaceutical

SAMSCA™ Tablets 15mg (tolvaptan), Vasopressin V2-Receptor Antagonist, Receive Regulatory Approval in Japan
October 25, 2010
Otsuka Pharmaceutical

New Release of Medicated Skin Wash in 500mL Pump-style Economy Size and Refill Pouch Available from November 12, 2010
October 6, 2010
Otsuka Pharmaceutical

OTSUKA ANNOUNCES PHASE 3 ARIPIPRAZOLE INTRAMUSCULAR (IM) DEPOT TRIAL INTERIM ANALYSIS REVEALS EFFICACY CRITERIA MET
October 5, 2010
Otsuka Pharmaceutical

OTSUKA OPENS FIRST OFFICE IN CANADA Important Milestone for Growing North American Pharmaceutical Operations
September 29, 2010
Otsuka Pharmaceutical

Tweet Runners app for iPhone released on September 29th Tweet Runners and Amino-Value keep runners going
September 28, 2010
Otsuka Pharmaceutical

Otsuka Pharmaceutical and Acucela Enter New Co-Development and Co-Promotion Agreement for OPA-6566 for Glaucoma
September 17, 2010
Otsuka Pharmaceutical

Antiepileptic Drug 'E Keppra® Tablet' with New Mechanism of Action Released on September 17
September 17, 2010
Taiho Pharmaceutical

Antineoplastic ABRAXANE® to be Launched Friday, September 24
September 13, 2010
Otsuka Pharmaceutical

The Results of CSPS 2, a Large-Scale Clinical Trial of Cilostazol in Preventing Recurrent Strokes, Posted on the Online Version of The Lancet Neurology
September 8, 2010
Otsuka Pharmaceutical

Renewed Package Design for Nature Made America's number one-selling vitamin, mineral and supplement brand
September 1, 2010
Otsuka Pharmaceutical

Construction of 'OPS-5', New Plant to Manufacture Active Pharmaceutical Ingredients in Saga Factory Completed on September 1
August 31, 2010
Otsuka Pharmaceutical

Publication of Environmental and Social Report 2010 - Featuring approaches to help build a low-carbon, recycling-oriented society, development of environment-conscious products and social action programs -
August 16, 2010
Otsuka Pharmaceutical

21st Annual Outdoor Concert Held at Otsuka Pharmaceutical Tokushima Wajiki Factory Exciting Summer in Wajiki '10 on August 13, 2010